Filtering

DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli

ECCO'20 Vienna

Year: 2020
Authors:

C. Douadi1, E. Vazeille1, C. Chambon2, M. Hébraud3, M. Dodel4, B. Pereira4, D. Coban4, A. Buisson4, N. Barnich1

1Clermont-Auvergne University, M2iSH Laboratory, Clermont-Ferrand, France, 2INRA, Plateforme d’Exploration du Métabolisme- Composante Protéomique PFEMcp, Saint-Genès-Champanelle, France, 3INRA, UMR Microbiologie Environnement Digestif Santé MEDiS, Saint-Genès-Champanelle, France, 4CHU, Gastro-entérologie, Clermont-Ferrand, France

DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon

ECCO'20 Vienna

Year: 2020
Authors:

S. Olafsson1, R.E. McIntyre1, T. Coorens2, T. Butler2, P. Robinson2, H. Lee-Six2, M. Sanders2, K. Arestang3, C. Dawson3, M. Tripathi4, K. Strongili3, Y. Hooks2, M.R. Stratton2, M. Parkes3, I. Martincorena2, T. Raine3, P.J. Campbell2, C.A. Anderson1

1Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, UK, 2Cancer, Aging and Somatic Mutations, Wellcome Trust Sanger Institute, Hinxton, UK, 3Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge, UK, 4Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

F. Branchi, C. Heldt, B. Siegmund, M. Schumann

Charité Universitätsmedizin Berlin – Campus Benjamin Franklin, Berlin, Germany

DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease

ECCO'20 Vienna

Year: 2020
Authors:

A. Unterweger1, J. Caesar1, P. Winkelmann1, A. Rüscher1, M. Seuß1, S. Breiteneicher5, J. Stallhofer5, F. Beigel5, M. Siebeck1, R. Gropp1

1Hospital of the Ludwig Maximilian Universität, General Visceral und Transplantation Surgery, München, Germany, 5Hospital of the Ludwig Maximilian Universität, Department of Medicine II, München, Germany

DOP53 PTPN2 and TiO2 in the pathogenesis of inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

J. Conde, M. Schwarzfischer, E. Katkeviciute, J. Häfliger, A. Niechcial, N. Brillant, K. Atrott, K. Bäbler, M. Scharl

Department of Gastroenterology and Hepatology, University Hospital Zurich, c/o University of Zurich, Zurich, Switzerland

DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis

ECCO'20 Vienna

Year: 2020
Authors:

D. Modos1,2,3, J. Brooks2,3,4, P. Sudhakar2,3,5, B. Verstockt5,6, B. Alexander-Dann1, A. Zoufir1, D. Fazekas2,7, S. Vermeire5,6, T. Korcsmaros2,3, A. Bender1

1Department of Chemistry, University of Cambridge, Cambridge, UK, 2Earlham Institute, Norwich, UK, 3Gut Microbes and Health Programme, Quadram Institute, Norwich, UK, 4Department of Gastroenterology, Norfolk and Norwich University Hospitals, Norwich, UK, 5Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium, 6Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 7Department of Genetics, Eötvös Loránd University, Budapest, Hungary

DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

ECCO'20 Vienna

Year: 2020
Authors:

G. Mantzaris1, B. Bressler2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, A. Yarur12

1Department of Gastroenterology, Evangelismos Hospital, Athens, Greece, 2Department of Gastroenterology, St. Paul’s Hospital, Vancouver, Canada, 3Department of Gastroenterology, Sheba Medical Center, Tel Aviv, Israel, 4Evidera, Real-World Evidence, Montreal, Canada, 5Evidera, Real-World Evidence, San Francisco, USA, 6Department of Medical Affairs, Takeda Pharmaceuticals USA Inc., Deerfield, USA, 7Department of Medical Affairs, Takeda Canada Inc., Oakville, Canada, 8Department of Medical Affairs, Takeda Hellas S.A. Athens, Athens, Greece, 9Department of Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 10Evidence Generation and Publications, Takeda Pharmaceuticals International, Singapore, 11Global Outcomes Research, Takeda Pharmaceuticals International, Boston, USA, 12Department of Gastroenterology, Medical College of Wisconsin, Milwaukee, USA

DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

W.J. Sandborn1, D.S. Rowbotham2, R.W.L. Leong3, C. Han4, Y. Zhou5, H. Zhang5, J. Johanns5, C. Marano6, S. Danese7, UNIFI Investigators

1Department of Gastroenterology, University of California San Diego, La Jolla, USA, 2Department of Gastroenterology and Hepatology, Auckland City Hospital, Auckland, New Zealand, 3Department of Gastroenterology, Concord and Macquarie University Hospitals, Sydney, Australia, 4Strategic Market Access, Janssen Global Services- LLC, Malvern, USA, 5Department of Clinical Biostats, Janssen Research and Development- LLC, Spring House, USA, 6Department of Immunology, Janssen Research and Development- LLC, Spring House, USA, 7Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy

DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study

ECCO'20 Vienna

Year: 2020
Authors:

N.A. Cohen1,2, N. Plevris3, U. Kopylov2,4, A. Grinman2,4, B. Ungar1,2, H. Yanai2,5, H. Leibovitzh2,5, N. Fliss1,2, A. Hirsch1,2, E. Ritter1,2, Y. Ron1,2, A. Bar-Gil Shitrit6,7, E. Goldin6,7, I. Dotan2,5, S. Ben-Horin2,4, C. Lees3,8, N. Maharshak1,2

1Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel, 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK, 4Department of Gastroenterology and Liver Diseases, Sheba Medical Center, Ramat Gan, Israel, 5IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikvah, Israel, 6Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel, 7Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel, 8The University of Edinburgh, Western General Hospital Campus, Center for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK

DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study

ECCO'20 Vienna

Year: 2020
Authors:

V.B. Biemans1, J.A.M. Sleutjes2, A.C. de Vries2, A.G. Bodelier3, G. Dijkstra4, B. Oldenburg5, M. Löwenberg6, A.A. van Bodegraven7, A.E. van der Meulen-de Jong8, N.K. de Boer9, N. Srivastava10, R.L. West11, T. Römkens12, C.S. Horjus Talabur Horje13, J.M. Jansen14, J. Hoekstra3, R.K. Weersma4, F.D. van Schaik5, F. Hoentjen1, M.J. Pierik15, Dutch Initiative on Crohn and Colitis (ICC)

1Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands, 2Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands, 3Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands, 4Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands, 5Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands, 6Department of Gastroenterology and Hepatology, Amsterdam University Medical Center- AMC, Amsterdam, The Netherlands, 7Department of Gastroenterology and Hepatology, Zuyderland Medical Center, Sittard, The Netherlands, 8Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands, 9Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands, 10Department of Gastroenterology and Hepatology, Haaglanden Medical Center, Den Haag, The Netherlands, 11Department of Gastroenterology and Hepatology, Sint Franciscus Hospital, Rotterdam, The Netherlands, 12Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands, 13Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, The Netherlands, 14Department of Gastroenterology and Hepatology, OLVG Hospital, Amsterdam, The Netherlands, 15Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands

DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

ECCO'20 Vienna

Year: 2020
Authors:

J.F. Colombel1, M.T. Osterman2, P. Ibanez3, A.J. Thorpe4, H. Zhang4, N. Lawendy4, C. Su4, W. Reinisch5

1Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA, 2Penn Presbyterian Medical Center, Philadelphia, PA, USA, 3Clínica Las Condes, Santiago, Chile, 4Pfizer Inc., Collegeville, PA, USA, 5Medical University of Vienna, Vienna, Austria

DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, K. Subramanian2, J. Van Zyl3, S. Adsul4, D. Lindner5, J. Roth6, S. Vermeire7

1Department of Gastrointestinal Immunopathology, Humanitas University, Milan, Italy, 2Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia, 3University of the Free State, Department of Gastroenterology, Bloemfontein- Free State, South Africa, 4Department of Global Medical Affairs, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Chief Medical Office, Global Medical Research, Takeda Pharmaceuticals International AG, Zurich, Switzerland, 7Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

ECCO'20 Vienna

Year: 2020
Authors:

G.R. Lichtenstein1, E.V. Loftus Jr2, S.C. Wei3, A.O. Damião4, D. Judd5, N. Lawendy5, G. Chan5, H. Zhang5, W. Wang5, A.J. Thorpe5, S. Bloom6

1Division of Gastroenterology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, USA, 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, 3Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Province of China, 4Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil, 5Pfizer Inc., Collegeville, PA, USA, 6University College London Hospitals NHS Foundation Trust, London, UK, UK

DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre

ECCO'20 Vienna

Year: 2020
Authors:

M. Rottoli1, M. Tanzanu1, G. Vago1, A. Belvedere1, D. Parlanti1, P. Pezzuto1, S. Bosi1, F. Caputo1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

1Surgery of the Alimentary Tract, Sant’Orsola Hospital, Alma Mater Studiorum University of Milan, Bologna, Italy, 2Inflammatory Bowel Disease Unit, Sant’Orsola Hospital, Alma Mater Studiorum University of Milan, Bologna, Italy

DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial

ECCO'20 Vienna

Year: 2020
Authors:

G. Fiorino1, M. Allocca1, D. Gilardi1, M. Alfieri1, P. Danieli1, F. Furfaro1, G. Roda1, L. Loy1, A. Zilli1, S. Radice1, L. Peyrin-Biroulet2, S. Danese1

1Department of Gastroenterology, IBD Center, Humanitas Research Hospital, Rozzano, Italy, 2Inserm U954, Nancy University Hospital, IBD Unit, Nancy, France

DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

J. WONG1, M. Bursavich2, N. Blanco1, A. Camblin1, L. Cappellucci1, R. Cohen1, D. Cui3, M. Krumpoch1, C. Zhong2, K. Hahn2, D. Lee3, B. Lippa2, F.Y. Lin4, A. Lugovsky5, M. McShea4, S. Mostafavi4, T. Moy1, A. Sullivan6, D. Troast2, L. Wang1, B. Rogers2

1Department of Biology, Morphic Therapeutic, Waltham, USA, 2Department of Chemistry, Morphic Therapeutic, Waltham, USA, 3Department of Drug Metabolism and Pharmacokinetics, Morphic Therapeutic, Waltham, USA, 4Department of Structural Biology, Morphic Therapeutic, Waltham, USA, 5Department of Development, Morphic Therapeutic, Waltham, USA, 6Department of Translational Sciences, Morphic Therapeutic, Waltham, USA

DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity

ECCO'20 Vienna

Year: 2020
Authors:

B. Steere1, J. Schmitz1, N. Powell2, R. Higgs1, K. Gottlieb1, Y. Liu1, B. Jia1, J.L. Tuttle3, W.J. Sandborn4, B.E. Sands5, V. Krishnan1

1Eli Lilly and Company, Lilly Biomedicines, Indianapolis IN, USA, 2Centre for Inflammation Biology and Cancer Immunology, King’s College London, London, UK, 3Lilly Biotechnology Center, Eli Lilly and Company, Sand Diego, CA, USA, 4Division of Gastroenterology, University California San Diego, La Jolla, CA, USA, 5Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

G. Roda PhD1, D. Dunkin2, C. Correale1, S. Vetrano1, F. Merlino3, L. Marinelli3, E. Novellino3, L. Mayer4, G. Yeretssian5,6, S. Danese1

1Humanitas Research Hospital, IBD Center, Milano, Italy, 2Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology and The Mindich Child Health and Development Institute, New York, USA, 3Department of Pharmacy, University of Naple, Naple, Italy, 4Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, USA, 5The Leona M. and Harry B. Helmsley Charitable Trus, The Leona M. and Harry B. Helmsley Charitable Trust, New York, USA, 6Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, USA

DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway

ECCO'20 Vienna

Year: 2020
Authors:

J. Shin1, N. Ha1, D. Bae1, Y.J. Lee1, Y.I. Choi1, K.H. Ryu1, G.S. Youn2, J. Park2

1Department of Non-clinical Study, Chong Kun Dang Pharm. Research Institute, Youngin-si, Korea Republic of, 2Department of Biomedical Science, Hallym University, Chuncheon, Korea Republic of

DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway

ECCO'20 Vienna

Year: 2020
Authors:

Y. XU1, M. zhang2, G. Xu2, X. Zou2

1Department of Gastroenterology, Nanjing Medical University Affiliated Drum Tower Clinical Medical College, Nanjing, China, 2Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China